GlassScriptPhysician profile
Aprile Harris
NPI 1831133701
$4,561.50
in general payments reported to CMS, 2019-2025
35 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $888 · 2023: $788 · 2024: $1,344 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281 · Education: $99.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.14 |
| Education | $99.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $872.16 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $441.67 | 2021-2025 | |
| Ardelyx, INC. | $368.37 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Fresenius USA Marketing, INC. | $304.23 | 2022-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $289.42 | 2022-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $274.64 | 2024-2025 | Tarpeyo |
| Amgen INC. | $212.30 | 2024-2025 | Tavneos |
| Travere Therapeutics, INC. | $199.76 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.10 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $180.19 | 2022-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $175.68 | 2022-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $142.21 | 2023-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $137.30 | 2022-2023 | Veltassa, Korsuva |
| Medtronic, INC. | $84.79 | 2024 | Ellipsys Vascular Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $77.86 | 2022-2024 | Gattex |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $67.03 | 2022-2023 | |
| Glaxosmithkline, LLC. | $61.44 | 2023-2024 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $60.75 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.97 | 2025 | |
| Lilly USA, LLC | $49.29 | 2021-2025 | Jardiance |
| Abbvie INC. | $46.70 | 2021-2022 | |
| Scpharmaceuticals INC. | $37.89 | 2025 | |
| Ani Pharmaceuticals, INC. | $33.77 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $29.91 | 2022 | |
| Kyowa Kirin, INC. | $28.69 | 2023 | Crysvita |
| Pharmacosmos Therapeutics INC. | $18.48 | 2025 | Monoferric |
| Radius Health, INC. | $17.81 | 2021 | |
| Eisai INC. | $17.41 | 2021 | |
| Novo Nordisk INC | $16.83 | 2021 | |
| Cmp Pharma, INC. | $15.05 | 2025 | Norliqva, Atorvaliq, Liqrev |
| Supernus Pharmaceuticals, INC. | $14.72 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.50 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.58 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aprile Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.